Profound Medical said it won an investigation device exemption from the FDA for a clinical trial of its device to treat prostate cancer.
The Toronto-based medical device company said it hopes to begin enrolling patients later this year in the Tulsa trial.
The Profound device combines thermal ultrasound with real-time MRI guidance in a single outpatient session to treat localized prostate cancer, according to a press release.